Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
LongBio Pharma
AddedJul 2, 2026
UpdatedJul 2, 2026
LongBio Pharma

LongBio Pharma

Series C

LongBio Pharma is a clinical-stage biopharmaceutical company developing innovative biologics for allergic and autoimmune diseases.

HQ
Changshu, Jiangsu, CN
Founded
2020
Overview
Analysis
Compare
Fundraising
Employees
News
Website

LongBio Pharma (Suzhou) Co., Ltd. is a clinical-stage biopharmaceutical company established in 2020 with operations in Shanghai and Changshu, Suzhou, China. It focuses on in-house discovery and development of biologics for allergic and autoimmune diseases leveraging high-affinity antibody and bi-functional antibody platforms.

Lead candidate LP-003, a next-generation anti-IgE antibody, is in Phase III for seasonal allergic rhinitis and has shown superior efficacy versus omalizumab in Phase II CSU trials. LP-005, a bifunctional C5/C3b complement inhibitor, is in Phase II for PNH. The company completed its IPO on the Hong Kong Stock Exchange (01779.HK) in June 2026 backed by Qiming Venture Partners.

LongBio Pharma - Similar Companies

Long Bridge Medical logo

Long Bridge Medical

HI-Bio logo

HI-Bio

hibio.com

Arranta Bio logo

Arranta Bio

BioRay Pharmaceuticals logo

BioRay Pharmaceuticals

iBio logo

iBio

ibioinc.com

Longeveron logo

Longeveron

longeveron.com

Actinobac Biomed logo

Actinobac Biomed

Longevity Biotech logo

Longevity Biotech

Larrk Bio logo

Larrk Bio

Upstream Bio logo

Upstream Bio

upstreambio.com

Surf Bio logo

Surf Bio

surf.bio

Santa Ana Bio logo

Santa Ana Bio

santaanabio.com

Lucaspye BIO logo

Lucaspye BIO

lucaspyebio.com

Innovent Biologics logo

Innovent Biologics

Revolo Biotherapeutics logo

Revolo Biotherapeutics

revolobio.com

LongBio Pharma - Quick Facts

Who are LongBio Pharma's competitors?

Companies similar to LongBio Pharma include Long Bridge Medical, HI-Bio, Arranta Bio and BioRay Pharmaceuticals.

When was LongBio Pharma founded?

LongBio Pharma was founded in 2020.

Where is LongBio Pharma's headquarters located?

LongBio Pharma's headquarters is located in Changshu, Jiangsu, CN.

When was LongBio Pharma's last funding round?

LongBio Pharma's most recent funding round was for $200M (USD) in June 2025.

How much has LongBio Pharma raised to-date?

As of Jun 4, 2025, LongBio Pharma has raised a total of $300M (USD).

LongBio Pharma - Classification

Industry
  • Biotechnology
Tags
  • Biotech